Capsaicin News and Research

RSS

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

16 Jun 2011

New insight into itch and pain

A new study of itch adds to growing evidence that the chemical signals that make us want to scratch are the same signals that make us wince in pain.

3 May 2011

NeurogesX first quarter revenue is $3.2 million for 2011

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its first quarter ended March 31, 2011.

30 Apr 2011

Red pepper consumption can help manage appetite

Spicing up your daily diet with some red pepper can curb appetite, especially for those who don't normally eat the popular spice, according to research from Purdue University.

26 Apr 2011

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.

12 Apr 2011

Nature's Health announces record sales of 145% for Australian Dream pain relief cream

Nature's Health Connection has announced record sales of their Australian Dream pain relief cream. After a successful television advertising campaign produced by CPG specialists Western Creative, Inc. that highlights Australian Dream's Empty Jar Guarantee, unit retail sales of the product have increased an astonishing 145% over the course of the last year.

18 Mar 2011

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Patients in Sweden living with peripheral neuropathic pain are set to gain access to a new treatment option which can provide pain relief for up to three months following a single 30- or 60-minute application. The new treatment patch uses capsaicin - the substance found in chilli peppers which gives them their 'heat' - to change the function of pain sensing nerves in the area of skin affected.

1 Mar 2011

Research discovers new role of TRPV1 receptors in regulation of locomotor activity

Research by a Barrow Neurological Institute scientist on the thermoregulatory effects of a receptor more commonly studied for its role in pain is the cover story in the Feb. 2 issue of the Journal of Neuroscience.

2 Feb 2011

CMS grants Qutenza J-code to NeurogesX

NeurogesX, Inc. a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a unique, Level II Health Care Common Procedural Coding System (Level II HCPCS), commonly referred to as a J-code, for Qutenza (capsaicin) 8% patch.

19 Nov 2010

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

3 Nov 2010

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

19 Oct 2010

Capsaicin linked to skin cancer

The September cover story of the nation's leading cancer journal, "Cancer Research," features a new study from The Hormel Institute, University of Minnesota, that links capsaicin, a component of chili peppers, to skin cancer. While the molecular mechanisms of the cancer-promoting effects of capsaicin are not clear and remain controversial, The Hormel Institute has shown a definite connection to formation of skin cancer through various laboratory studies.

3 Sep 2010

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its second quarter ended June 30, 2010.

7 Aug 2010

Long-term dietary consumption of capsaicin can reduce blood pressure: Research

For those with high blood pressure, chili peppers might be just what the doctor ordered, according to a study reported in the August issue of Cell Metabolism, a Cell Press publication. While the active ingredient that gives the peppers their heat-a compound known as capsaicin-might set your mouth on fire, it also leads blood vessels to relax, the research in hypertensive rats shows.

4 Aug 2010

Capsaicin may cause weight loss, fight fat buildup: Study

Capsaicin, the stuff that gives chili peppers their kick, may cause weight loss and fight fat buildup by triggering certain beneficial protein changes in the body, according to a new study on the topic. The report, which could lead to new treatments for obesity, appears in ACS' monthly Journal of Proteome Research.

22 Jul 2010

Chili peppers may cause weight loss and fight fat buildup, says study

Scientists are reporting new evidence that capsaicin, the stuff that gives chili peppers their kick, may cause weight loss and fight fat buildup by triggering certain beneficial protein changes in the body. Their study, which could lead to new treatments for obesity, appears in ACS' monthly Journal of Proteome Research.

3 Jun 2010

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Icagen, Inc. reported today its financial results and operational highlights for the first quarter ended March 31, 2010. For the first quarter of 2010, the Company reported revenues of $1.5 million and a net loss of $3.2 million. As of March 31, 2010, the Company's cash and cash equivalents totaled $14.3 million.

7 May 2010

NeurogesX announces $40 million royalty financing agreement with Cowen Royalty

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that that it has entered into a $40 million royalty financing agreement with Cowen Healthcare Royalty Partners, L.P. ("Cowen Royalty").

30 Apr 2010

Study examines potential health benefits of DCT

Imagine your delight while enjoying your favorite Mexican food - perhaps a fully loaded bean burrito topped with an ample supply of thinly sliced jalepeño peppers. What happens when you bite into a few more peppers than you bargained for? Does this thought conjure up the thought of a little heat? Perhaps even a bit of sweat on the brow? Indeed, food scientists can tell you that hot peppers contain a substance called capsaicin that not only adds spice to our foods but can actually cause your body to heat up.

28 Apr 2010

Physician panel to discuss issues related to Qutenza at Investor Day

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City

24 Apr 2010